Mirum Pharmaceuticals, Inc.: Leerink Partners cuts target price to $140 from $154
MIRM•Leerink Partners cut its target price for Mirum Pharmaceuticals to $140 from $154.
Related News
Yum Brands: RBC raises target price to $180 from $170
YUM•
Cullinan Therapeutics receives buy rating with $35 price target
CGEM•
Investors poised for gridlock with Trump as Democrats projected to sweep Congress
SPY•
Waters Corp: JP Morgan raises target price to $470 from $435
WAT•
Australia social media teen ban a 'modest' step, says government in top court challenge
RDDT•